Empiric Antibiotics for Multi-Drug Resistant Pneumonia

Introduction to Empiric Antibiotic Therapy

The Infectious Diseases Society of America recommends triple-drug combination therapy for suspected multi-drug resistant hospital-acquired or ventilator-associated pneumonia, consisting of an antipseudomonal β-lactam, a second antipseudomonal agent from a different class, and MRSA coverage 1, 2

High-risk criteria for MDR pathogens include prior intravenous antibiotic use within 90 days, five or more days of hospitalization prior to pneumonia onset, septic shock at time of presentation, ARDS preceding pneumonia, acute renal replacement therapy prior to onset, and mechanical ventilation, as stated by the Infectious Diseases Society of America 2, 3
Patients with two or more MDR risk factors have a higher rate of MDR pathogens, making risk stratification critical for appropriate empiric therapy selection, according to the Infectious Diseases Society of America 2

For high-risk MDR pneumonia, the Infectious Diseases Society of America recommends triple-drug combination therapy, including an antipseudomonal β-lactam, a second antipseudomonal agent from a different class, and MRSA coverage 1, 2, 4
The American Thoracic Society suggests that monotherapy with a single antipseudomonal agent is appropriate for low-risk pneumonia, with options including piperacillin-tazobactam, cefepime, levofloxacin, imipenem, and meropenem 2, 3

The Infectious Diseases Society of America recommends that all IV antibiotics be infused over 30 minutes, with extended infusions considered for β-lactams to optimize pharmacokinetic/pharmacodynamic parameters 1, 4
Empiric treatment regimens must be informed by local distribution of pathogens and their antimicrobial susceptibilities, as institutional resistance patterns vary significantly, according to the Infectious Diseases Society of America 1, 2
The Infectious Diseases Society of America suggests that treatment duration should be 7-8 days for hospital-acquired pneumonia if clinical stability is achieved 4, 3

The Infectious Diseases Society of America states that aminoglycoside regimens were associated with lower clinical response rates with no mortality benefit, making fluoroquinolones the preferred second antipseudomonal agent when possible 1
For severe penicillin allergy, the Infectious Diseases Society of America recommends adding MSSA coverage to aztreonam due to its lack of gram-positive activity 1, 4
The Infectious Diseases Society of America suggests that colistin and polymyxin B should be reserved only for settings with high prevalence of carbapenem-resistant organisms and local expertise in using these medications, given significant nephrotoxicity risks 1, 2
The Infectious Diseases Society of America recommends obtaining appropriate respiratory cultures before initiating antibiotics, then de-escalating therapy once culture results return to narrow coverage and reduce selection pressure for resistance 1, 3